Data Sheet 1_Evaluation of the therapeutic effect of new hypoglycemic drugs on patients wi

16 randomized controlled trials with data from 14,710 patients are synthesized in this systematic review and network meta-analysis. The study evaluates novel glucose-lowering therapies for patients with heart failure with reduced ejection fraction and type 2 diabetes, assessing composite cardiovascular outcomes. Author Xin-Rao Chen published the analysis on figshare in May 2026.

Use Cases

• Compare the efficacy of SGLT2 inhibitors like Sotagliflozin and Dapagliflozin based on composite cardiovascular death and heart failure hospitalization outcomes.
• Analyze the impact of different therapies on surrogate markers like Left Ventricular Ejection Fraction (LVEF) and N-terminal pro-B-type natriuretic peptide (NT-proBNP).
• Evaluate renoprotective effects based on changes in Estimated Glomerular Filtration Rate (eGFR) reported for Empagliflozin.
• Assess glycemic control effectiveness based on Glycated hemoglobin (HbA1c) reduction data for Vildagliptin.

Strengths

• Analysis is based on 16 randomized controlled trials encompassing 14,710 patients.
• The study protocol was prospectively registered with PROSPERO (CRD420251269519).
• Quality appraisal was performed using the Cochrane Risk of Bias Tool 2.0 and Confidence in Network Meta-Analysis (CINeMA) framework.

Limitations

• The dataset is a 2.4 MB DOCX file containing a review article; the underlying raw trial data is not provided.
• Column-level documentation for any underlying data is absent; field semantics must be inferred from the manuscript text.
• The row count for any potential tabular data within the document is unknown.

Provenance

Source

figshare

Collection Method

Systematic literature review and network meta-analysis of randomized controlled trials from PubMed, EMBASE, and the Cochrane Library.

Time Range

Literature search from database inception to September 1, 2025.

Freshness

Last updated 2026-05-08 05:55:49